Characteristics of adverse reactions among antipsychotic drugs using the Korean Adverse Event Reporting System database from 2010 to 2019
暂无分享,去创建一个
[1] A. Young,et al. Antipsychotics, the heartland of clinical psychopharmacology? , 2021, Journal of psychopharmacology.
[2] H. Khalil,et al. Characteristics of voluntary reporting of adverse drug events related to antipsychotics in Australia: 14-year analysis , 2021, Therapeutic advances in drug safety.
[3] Tae Young Lee,et al. Effectiveness of antipsychotic drugs in schizophrenia: a 10-year retrospective study in a Korean tertiary hospital , 2020, npj Schizophrenia.
[4] D. Cohen,et al. Aripiprazole in Children and Adolescents. , 2020, Journal of child and adolescent psychopharmacology.
[5] N. Iwata,et al. Trend survey on adverse event profiles of antipsychotic long-acting injections and oral agents using the Japanese adverse drug event report database , 2020, Psychiatry Research.
[6] O. Howes,et al. Making decisions about antipsychotics: a qualitative study of patient experience and the development of a decision aid , 2019, BMC Psychiatry.
[7] K. Sim,et al. Prescription of antipsychotic and concomitant medications for adult Asian schizophrenia patients: Findings of the 2016 Research on Asian Psychotropic Prescription Patterns (REAP) survey. , 2019, Asian journal of psychiatry.
[8] Y. Ahn,et al. Epidemiology of pharmaceutically treated depression and treatment resistant depression in South Korea , 2019, PloS one.
[9] Hyun Joo Lee,et al. Utilisation of medications among elderly patients in intensive care units: a cross-sectional study using a nationwide claims database , 2019, BMJ Open.
[10] Shin‐Tarng Deng,et al. Factors associated with adverse drug reaction occurrence and prognosis, and their economic impacts in older inpatients in Taiwan: a nested case–control study , 2019, BMJ Open.
[11] Mi Hyun Lee,et al. Trends in prescriptions for sedative–hypnotics among Korean adults: a nationwide prescription database study for 2011–2015 , 2018, Social Psychiatry and Psychiatric Epidemiology.
[12] T. Stroup,et al. Management of common adverse effects of antipsychotic medications , 2018, World psychiatry : official journal of the World Psychiatric Association.
[13] C. Correll,et al. Tardive dyskinesia risk with first‐ and second‐generation antipsychotics in comparative randomized controlled trials: a meta‐analysis , 2018, World psychiatry : official journal of the World Psychiatric Association.
[14] D. Song,et al. Nationwide Epidemiologic Study of Atypical Antipsychotic Use Among Pediatric Population with Mental Illness in Korea. , 2018, Journal of child and adolescent psychopharmacology.
[15] A. Wheeler,et al. Clozapine-related neutropenia, myocarditis and cardiomyopathy adverse event reports in Australia 1993–2014 , 2018, Psychopharmacology.
[16] M. Pompili,et al. Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine , 2018, Therapeutic advances in drug safety.
[17] K. Huybrechts,et al. International trends in antipsychotic use: A study in 16 countries, 2005–2014 , 2017, European Neuropsychopharmacology.
[18] C. Schneider,et al. Psychotropic medication use in Australia, 2007 to 2015: Changes in annual incidence, prevalence and treatment exposure , 2017, The Australian and New Zealand journal of psychiatry.
[19] V. Siskind,et al. Clozapine Response Rates among People with Treatment-Resistant Schizophrenia: Data from a Systematic Review and Meta-Analysis , 2017, Canadian journal of psychiatry. Revue canadienne de psychiatrie.
[20] A. Jablensky,et al. The 2016 Royal Australian and New Zealand College of Psychiatrists guidelines for the management of schizophrenia and related disorders , 2017, The Medical journal of Australia.
[21] C. Neoh,et al. Pharmacovigilance: pharmacists’ perspective on spontaneous adverse drug reaction reporting , 2017, Integrated pharmacy research & practice.
[22] Amar K. Das,et al. Differences in Antipsychotic-Related Adverse Events in Adult, Pediatric, and Geriatric Populations , 2017, Cureus.
[23] G. Juckel,et al. Effects of first-generation antipsychotics versus second-generation antipsychotics on quality of life in schizophrenia: a double-blind, randomised study. , 2016, The lancet. Psychiatry.
[24] K. Darton,et al. Results of a pilot cluster randomised trial of the use of a Medication Review Tool for people taking antipsychotic medication , 2016, BMC Psychiatry.
[25] T. Patel,et al. Adverse drug reactions in a psychiatric department of tertiary care teaching hospital in India: Analysis of spontaneously reported cases. , 2015, Asian journal of psychiatry.
[26] G. De Sarro,et al. Use of atypical antipsychotics in the elderly: a clinical review , 2014, Clinical interventions in aging.
[27] L. Kim,et al. A guide for the utilization of Health Insurance Review and Assessment Service National Patient Samples , 2014, Epidemiology and health.
[28] S. Frangou,et al. Antipsychotics use in children and adolescents: An on-going challenge in clinical practice , 2014, Journal of psychopharmacology.
[29] M. Sturkenboom,et al. Torsadogenic Risk of Antipsychotics: Combining Adverse Event Reports with Drug Utilization Data across Europe , 2013, PloS one.
[30] M. De Hert,et al. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review , 2013, Therapeutic advances in psychopharmacology.
[31] A. Medvedovici,et al. Drug-induced hypo- and hyperprolactinemia: mechanisms, clinical and therapeutic consequences , 2013, Expert opinion on drug metabolism & toxicology.
[32] H. Möller,et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects , 2013, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.
[33] C. Correll,et al. Safety and tolerability of antipsychotic polypharmacy , 2012, Expert opinion on drug safety.
[34] A. R. Maher,et al. Summary of the Comparative Effectiveness Review on Off-Label Use of Atypical Antipsychotics , 2012, Journal of managed care pharmacy : JMCP.
[35] M. De Hert,et al. Prevalence and severity of antipsychotic related constipation in patients with schizophrenia: a retrospective descriptive study , 2011, BMC gastroenterology.
[36] S. Leucht,et al. Second-generation antipsychotics and constipation: A review of the literature , 2011, European Psychiatry.
[37] R. Tandon. Antipsychotics in the treatment of schizophrenia: an overview. , 2011, The Journal of clinical psychiatry.
[38] S. Leucht,et al. Clozapine versus other atypical antipsychotics for schizophrenia. , 2010, The Cochrane database of systematic reviews.
[39] C. Adams,et al. Assessment of adverse effects in clinical studies of antipsychotic medication: survey of methods used , 2010, British Journal of Psychiatry.
[40] J. Muench,et al. Adverse effects of antipsychotic medications. , 2010, American family physician.
[41] B. Bégaud,et al. Antipsychotic prescribing trends: a review of pharmaco‐epidemiological studies , 2010, Acta psychiatrica Scandinavica.
[42] C. Hong,et al. Spontaneous reporting of adverse drug events by Korean regional pharmacovigilance centers , 2009, Pharmacoepidemiology and drug safety.
[43] C. Adams,et al. Systematic Overview of Cochrane Reviews for Anticholinergic Effects of Antipsychotic Drugs , 2009, Journal of clinical psychopharmacology.
[44] I. Chaudhry,et al. Ethnicity and psychopharmacology , 2008, Journal of psychopharmacology.
[45] R. Ferner,et al. Ethnic Differences in the Risks of Adverse Reactions to Drugs Used in the Treatment of Psychoses and Depression , 2008, Drug safety.
[46] N. Choi,et al. [Adverse drug reaction surveillance system in Korea]. , 2007, Journal of preventive medicine and public health = Yebang Uihakhoe chi.
[47] Aileen O'Brien. Starting Clozapine in the Community , 2004, CNS drugs.
[48] G. Remington,et al. Clinical characteristics and associated factors in antipsychotic-induced akathisia of Asian patients with schizophrenia , 2003, Schizophrenia Research.
[49] F. Micheli,et al. Quetiapine and Essential Tremor , 2002, Clinical neuropharmacology.
[50] W. Glazer,et al. Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. , 2000, The Journal of clinical psychiatry.
[51] David Taylor,et al. Tolerability of Atypical Antipsychotics , 2000, Drug safety.
[52] P. Masand,et al. Side effects of antipsychotics in the elderly. , 2000, The Journal of clinical psychiatry.
[53] R. K. Day,et al. Psychomotor agitation: poorly defined and badly measured. , 1999, Journal of affective disorders.
[54] J. Adams,et al. Clozapine dosage, serum levels, efficacy, and side-effect profiles: a comparison of Korean-American and Caucasian patients. , 1996, Psychopharmacology bulletin.
[55] G. Hayes,et al. Clozapine-induced constipation. , 1995, The American journal of psychiatry.
[56] I. Edwards,et al. Proposed improvement to the WHO adverse reaction terminology (WHO‐ART) , 1993 .
[57] R. Meyboom,et al. Causality classification at pharmacovigilance centres in the european community , 1992 .